Q-omics provides the consensus-scored MFSD14B profile across patient tissues and cancer cell-line models. MFSD14B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MFSD14B is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, MFSD14B RNA expression shows 19,982 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where MFSD14B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD14B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD14B survival associations across molecular data types. MFSD14B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD14B RNA expression–survival associations across cancer types. High MFSD14B expression shows unfavorable associations in ACC, MESO, LIHC, HNSC and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MFSD14B RNA expression.
This table summarizes MFSD14B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD14B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD14B shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, STAD, HNSC and COAD. The BLCA box plot shows higher MFSD14B RNA expression in tumor versus normal tissue (log2 FC = +0.952, t-test p < 0.001).
This table shows molecular features associated with MFSD14B in patient tissues and cancer cell lines. In patient samples, MFSD14B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD14B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
